NCT07591285 is a Phase 1 clinical trial of SYS6051 in Advanced Solid Tumors, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd..

Who is sponsoring NCT07591285?

NCT07591285 is sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd..

What drugs are being tested in NCT07591285?

Interventions in NCT07591285: SYS6051.

What condition does NCT07591285 study?

NCT07591285 studies Advanced Solid Tumors.

Is NCT07591285 still recruiting?

NCT07591285 is currently not yet recruiting.

Last reviewed 2026-06-10 · How we verify

NCT07591285

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of SYS6051 in Subjects With Advanced Solid Tumors

Not yet recruiting Phase 1

What this trial tests

Phase 1 trial testing SYS6051 in Advanced Solid Tumors in 114 participants. Not yet recruiting.

Timeline

12 May 2026

30 June 2028

Quick facts

Lead sponsor	CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase	Phase 1
Status	Not yet recruiting
Enrollment	114
Start date	12 May 2026
Estimated completion	30 June 2028

Drugs / interventions tested

SYS6051

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. — full company profile →

Who can join

Eligibility, any sex, with Advanced Solid Tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other CSPC Megalith Biopharmaceutical Co.,Ltd. trials

Trials by the same sponsor.

NCT07526792 — SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma · Phase 3 · not yet recruiting
NCT07374549 — SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma · Phase 2 · not yet recruiting
NCT07406542 — A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer · Phase 3 · not yet recruiting
NCT07417735 — SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma · Phase 3 · not yet recruiting
NCT07442565 — SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07591285 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CSPC Megalith Biopharmaceutical Co.,Ltd.
Last refreshed: recently

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07591285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing